Skip to main content

Alnylam Pharmaceuticals Value Stock - Dividend - Research Selection

Alnylam pharmaceuticals

ISIN: US02043Q1076 , WKN: A0CBCK

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company\'s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Analysts Are Bullish on These Healthcare Stocks: DBV Technologies SA ��� American (DBVT), Veru (VERU)

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

CAMBRIDGE, Mass., March 01, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

Merck: All Eyes On Key Clinical Catalyst In March

Merck is an American biopharma powerhouse that has generated consistent compounding growth. Click here to read my analysis of MRK stock.

Alnylam Pharmaceuticals Stumbles From A High Perch

Alnylam's Q4 results were consistent with recently updated guidance. Read more to see my thoughts on ALNY stock and why it is a Buy.

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Penumbra (PEN) and Karuna Therapeutics (KRTX)

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder today’s conference call is being recorded. I would now like to turn the conference over to the company. Please go ahead. […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future

We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) business as it appears the...

Regeneron: Innovation And Disruption Done Right

Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.

Pharmas, medtechs dominate list of innovation leaders thanks to patents

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.